Primary Site >> Pancreatic Cancer
Gene >> DPYD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. PMID: 21528302 |
Ref: Clinical development of eniluracil: current status. PMID: 9830627 Ref: Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. PMID: 9914783 |
Ref: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. PMID: 10213225 |
Ref: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. PMID: 10853015 Ref: Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues. PMID: 10923099 Ref: Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. PMID: 11060767 Ref: Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors. PMID: 11081574 |
Ref: Up-regulation in dihydropyrimidine dehydrogenase activity by raltitrexed causes antagonism in combination with 5-fluorouracil. PMID: 14981911 |
Ref: Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. PMID: 15492566 Ref: [The thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio in pancreatic cancer]. PMID: 15634525 |
Ref: Genetic factors influencing pyrimidine-antagonist chemotherapy. PMID: 16041392 Ref: Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. PMID: 16314628 |
Ref: A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. PMID: 16466986 |
Ref: Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. PMID: 17443278 Ref: Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. PMID: 17695509 Ref: Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. PMID: 17762760 Ref: Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? PMID: 18632519 |
Ref: High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. PMID: 18309485 Ref: Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? PMID: 18326935 Ref: Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU. PMID: 18691340 Ref: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. PMID: 19020767 |
Ref: Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. PMID: 19287123 Ref: Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. PMID: 19571608 |
Ref: Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? PMID: 19921195 Ref: Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer. PMID: 20072795 |
Ref: Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. PMID: 21487324 Ref: [Expression of dihydropyrimidine dehydrogenase negatively correlated with the prognosis of pancreatic ductal adenocarcinoma]. PMID: 21612699 Ref: Impact of dihydropyrimidine dehydrogenase and gamma-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer. PMID: 22977627 |
Ref: Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. PMID: 22086444 |
Ref: Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. PMID: 25833230 |
Ref: Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. PMID: 26495780 Ref: Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. PMID: 27278667 |
Ref: A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. PMID: 28296649 Ref: Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. PMID: 28476815 Ref: Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. PMID: 28789372 |
Ref: Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. PMID: 29515256 |